Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HHS INSPECTOR GENERAL WANTS FD&C FELONY ENFORCEMENT POWERS "CLARIFIED"

Executive Summary

HHS INSPECTOR GENERAL WANTS FD&C FELONY ENFORCEMENT POWERS "CLARIFIED" by legislation, Inspector General Richard Kusserow told an Oct. 3 Senate hearing before Sen. Glenn's (D-Ohio) Governmental Affairs Committee. "Legislation is required to clarify the status of the investigative authority of the Inspector General, as well as the audit authority," Kusserow maintained. Glenn's committee is considering a statutory clarification of the 1978 Inspector General Act. The Ohio Democrat explained that the issue was raised last March when a Justice Department opinion contended that the investigative authority of inspectors general "is limited to cases where federal employees or federal funds are involved." The Justice Department memo, written by its Office of General Counsel, cites legislative history regarding the Inspectors General Act to support the department's contention that inspectors general may investigate government employees and operations and recipients of government funds but not private regulated entities that do not receive program funds. Kusserow argued at the hearing that such transfers are authorized by statute, even as interpreted by the Justice memorandum. ANDA sponsors "do get a program benefit," he reasoned. "Once FDA approves your drug, it's worth millions of dollars" even though the company "does not receive program dollars." While defending the IG's right to get involved in FDA investigations on Capitol Hill, Kusserow has backed down a bit in communications with FDA (see related story, previous page). A strict interpretation of the memo would be "outlandish," Kusserow said, because it would place "a cloud over" inspector general investigations. He pointed out "the irony" that, despite the memorandum, there has been "no change with regard to the Justice Department in their criminal division. The U.S. attorneys continue to take our cases." Nonetheless, he added, clarification of the authority intended by Congress "is very important."

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Latest Headlines
See All
UsernamePublicRestriction

Register

PS016354

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel